Abstract
Alterations in cyclin-dependent kinases (CDK) are validated targets for cancer therapy. Palbociclib (palbo) selectively inhibits the CDK4/6/RB pathway. Platinum-based chemotherapy regimens (P) is the backbone for systemic therapy of many solid tumors. CDK4/6 inhibitors potentiate the efficacy of P in preclinical models. This study used an escalating-deescalating design to establish the safety and recommended phase II doses (RP2D) of the combination of palbo and cisplatin (cis; Arm A) or carboplatin (carbo; Arm B) in patients with advanced solid malignancies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
